Guolian Securities: Increased attention to tumor immunology, recommend focusing on targeted drugs such as PD1/IL2 in pharmaceutical companies.
With the increasing attention to tumor immunity, and the successive launch of advantageous products, bullish on PD1/IL2 and PD1/IL15 targeted drugs.
Express News | Exact Sciences Corp : Piper Sandler Cuts Target Price to $75 From $80
Analysts Offer Insights on Healthcare Companies: Alignment Healthcare (ALHC), Exact Sciences (EXAS) and Fulcrum Therapeutics (FULC)
DoorDash And Exact Sciences Are Among Top 10 Large Cap Gainers Last Week (July 28-Aug 3): Are The Others In Your Portfolio?
Scotiabank Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $70
Exact Sciences Corporation (NASDAQ:EXAS) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Decoding Exact Sciences Corp (EXAS): A Strategic SWOT Insight
Top Gap Ups and Downs on Thursday: META, TM, APD and More
Crude Oil Moves Lower; Moderna Shares Plunge
Exact Sciences Analysts Slash Their Forecasts After Q2 Results
Exact Sciences Price Target Cut to $67.00/Share From $91.00 by Benchmark
Dow Dips Over 500 Points; ISM Manufacturing PMI Falls In July
Air Products Posts Upbeat Earnings, Joins Meta, Exact Sciences, Shake Shack, Clearwater Analytics And Other Big Stocks Moving Higher On Thursday
Exact Sciences Up Nearly 25%, On Track for Largest Percent Increase Since September 2020 -- Data Talk
UBS Cuts Exact Sciences' Price Target to $61 From $66, Maintains Neutral Rating
Trending Stocks Today | Exact Sciences Soars 23.62%
Exact Sciences Is Maintained at Buy by Stifel
Guardant Launches Newly Approved Colorectal Cancer Test in U.S.
Stifel Maintains Buy on Exact Sciences, Lowers Price Target to $82
Exact Sciences Analyst Ratings